SCHEMBL7414770

SCHEMBL7414770

COc1ccc(OC(F)F)c(CBr)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.49
IDO1 P14902 2/20 0.44
ADRA1A P35348 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
GAA P10253 1/20 0.42
HSD17B10 Q99714 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
PDE4B Q07343 2/20 0.41
AOC3 Q16853 1/20 0.40
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28041255 0.83 ADRA1A (0.51) HTR2AIDO1ADRA1ATAAR1GAA
SCHEMBL7418739 0.83 HSD17B10 (0.45) HTR2AIDO1ADRA1ATAAR1HSD17B10
SCHEMBL1264360 0.82 HTR2A (0.62) HTR2AIDO1ADRA1ATAAR1HSD17B10
SCHEMBL18149258 0.79 ALDH1A1 (0.44) GAAMEN1POLBMAPTKMT2A
SCHEMBL18150301 0.77 SLC6A4 (0.39) HTR2APDE4BCYP2D6
SCHEMBL18151138 0.77 L3MBTL1 (0.38) MEN1KMT2A
SCHEMBL30646923 0.76 L3MBTL1 (0.48) HTR2AHSD17B10MEN1POLBMAPT
SCHEMBL1097224 0.76 L3MBTL1 (0.48) HTR2AHSD17B10MEN1POLBMAPT
SCHEMBL20489173 0.76 MTNR1A (0.52) HTR2AIDO1ADRA1ATAAR1GAA
SCHEMBL16953984 0.75 MAPT (0.48) HTR2AADRA1AGAACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1163214-A1 GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 Merck Frosst Canada & Co. (CA) 2001-12-19 EP disclosed
US-6225288-B1 IMPLICATED IN MODULATING APOPTOSIS; TREATMENT OF:CARDIAC AND CEREBRAL ISCHEMIA/REPERFUSION INJURY, SPINAL CORD INJURY AND ORGAN DAMAGE DURING TRANSPLANTATION, CHRONIC NEURODEGENERATIVE DISEASES, IMMUNODEFICIENCY, DIABETES, ALOPECIA, AGING MERK FROSST CANADA & CO. (CA) 2001-05-01 US disclosed
WO-2000055127-A1 GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 MERCK FROSST CANADA & CO. (CA) 2000-09-21 WO disclosed